Cyclin Dependent Kinase 9 - 2018 Pipeline Review, H1 - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Cyclin Dependent Kinase 9 - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC or EC

The report reviews targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved in targeted therapeutics and enlists all their major and minor projects.

The report assesses targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news and deals related to targeted therapeutics.

Companies Mentioned

Astex Pharmaceuticals Inc AstraZeneca Plc Bayer AG Cyclacel Pharmaceuticals Inc Jyant Technologies Inc MEI Pharma Inc Tolero Pharmaceuticals Inc Vichem Chemie Research Ltd ViroStatics srl

Key Topics Covered

Introduction Report Coverage Overview Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Companies Involved in Therapeutics Development Drug Profiles

For more information about this report visit https://www.researchandmarkets.com/research/prtpkr/cyclin_dependent?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005969/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 01:57 PM/DISC: 06/11/2018 01:57 PM


Update hourly